Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech disclosures can feel like a second language—especially when GRAIL’s 10-K spells out hundreds of pages of clinical trial statistics, cash-burn tables, and regulatory risk factors tied to its Galleri multi-cancer early detection test. Finding the pivotal trial read-outs or decoding executive stock moves before major data releases shouldn’t require a medical degree.
Stock Titan’s platform turns that challenge into a two-minute task. Our AI-powered summaries convert dense narratives into plain English, so understanding GRAIL SEC documents with AI is as direct as reading a headline. Receive real-time alerts the moment a GRAIL Form 4 insider transactions real-time notice hits EDGAR, review a distilled GRAIL quarterly earnings report 10-Q filing, or open a GRAIL 8-K material events explained brief that pinpoints new clinical milestones.
Use the filings that matter most:
- GRAIL annual report 10-K simplified – track R&D outlays, patent positions, and Galleri commercialization strategy.
- 10-Q trends – rapid GRAIL earnings report filing analysis for cash-runway checks.
- GRAIL insider trading Form 4 transactions – uncover buying or selling before clinical data drops.
- GRAIL proxy statement executive compensation – see how trial success metrics drive pay packages.
Whether you’re monitoring GRAIL executive stock transactions Form 4 or verifying a new partnership disclosed in an 8-K, our comprehensive, continuously updated library ensures GRAIL SEC filings explained simply. Skip the jargon, focus on the insight, and make faster, better-informed decisions about this precision-oncology pioneer.
GRAIL, Inc. (GRAL) reported insider stock sales by President Joshua Ofman on a Form 4. On 10/15/2025, he sold 8,865 shares of common stock at an average price of $76.0276. On 10/16/2025, he sold 6,114 shares at an average price of $82.01.
Following these transactions, Ofman beneficially owns 381,818 shares directly. The filing notes the sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
GRAIL, Inc. (GRAL) reported a director equity grant. On 10/15/2025, Director Steven Mizell acquired 267 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan. The grant was issued in lieu of
GRAIL, Inc. (GRAL) reported an insider transaction on a Form 4. CEO and director Robert Ragusa executed an automatic sell-to-cover of 7,239 shares of common stock on 10/15/2025 at a weighted average price of $68.88 to cover withholding taxes upon award vesting and share delivery.
After the transaction, Ragusa beneficially owned 727,388 shares, held directly. The sale was reported under transaction code “S” and occurred as part of a block trade executed in multiple transactions.
Insider sale reported for GRAIL, Inc. (GRAL). The reporting person, Joshua J. Ofman (an officer listed as President), sold 81,385 shares of GRAIL common stock on
CRCM and affiliated entities reported ownership of common stock of Grail, Inc. Combined filings show CRCM LP and related funds/vehicles collectively report beneficial ownership of 1,800,651 shares, representing 5% of the outstanding common stock based on a 36,047,799 share denominator. Individual CRCM vehicles report holdings ranging from 206,666 to 937,153 shares; the largest single reported holder among the group is CRCM G SPV, LP with 937,153 shares (2.6%). The filings state the shares are not held to change or influence control and include standard disclaimers of beneficial ownership by the investment manager and general partners. The reporting date for the required event is
Grail, Inc. (GRAL): Schedule 13G/A (Amendment No. 2) — CRCM LP and affiliated entities reported beneficial ownership of 1,842,651 shares of Grail common stock, representing 5.11% of the class. The group holds shared voting and dispositive power over 1,842,651 shares and no sole power. Percentages are based on 36,047,799 shares outstanding as of June 30, 2025.
Reporting persons include CRCM Opportunity Funds III & IV, CRCM Institutional Master Fund (BVI), CRCM G SPV, CRCM LP, CRCM LLC, their general partners, and Chun R. Ding. They certified the holdings were not acquired to change or influence control.
Joshua J. Ofman, President of GRAIL, Inc. (GRAL), reported a sale of 9,692 shares of common stock on 10/02/2025 at a reported price of $64.0025 per share. After the transaction he beneficially owns 478,182 shares. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, and the Form 4 was signed by an attorney-in-fact on 10/03/2025. The report is a routine Section 16 disclosure showing an officer-initiated disposition under an established trading plan.
GRAIL, Inc. (GRAL) filed a Form 144 reporting a proposed sale of 89,237 shares of common stock with an aggregate market value of $5,848,592.98, based on an approximate sale date of 10/06/2025 on NASDAQ. The filing shows the securities were originally acquired on 10/03/2024 upon vesting of restricted stock units under the issuer's equity incentive plans; the acquisition amount reported is 152,810 shares and the stated nature of payment is services rendered with a payment date of 10/03/2025. The filing also discloses two recent sales by Joshua J. Ofman: 4,202 shares sold on 08/19/2025 for $134,548.04 and 9,692 shares sold on 10/02/2025 for $601,485.52. Certain filer identification fields (CIK/CCC and filer contact name) and issuer address details are not provided in the visible content.
GRAIL, Inc. filed a Form 144 disclosing a proposed sale of 9,692 common shares, acquired as restricted stock units on 04/30/2025, with an aggregate market value of $601,485.52. The filing identifies the broker as Morgan Stanley Smith Barney LLC and lists an approximate sale date of 10/02/2025 on NASDAQ. The filing also reports a recent sale by the same person of 4,202 shares on 08/19/2025 for gross proceeds of $134,548.04. The issuer's shares outstanding are listed as 36,047,799. The notice states the seller represents they possess no undisclosed material adverse information and includes the standard Rule 10b5-1 and misstatement warnings.